164 related articles for article (PubMed ID: 38442793)
21. Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial.
Sartore-Bianchi A; Trusolino L; Martino C; Bencardino K; Lonardi S; Bergamo F; Zagonel V; Leone F; Depetris I; Martinelli E; Troiani T; Ciardiello F; Racca P; Bertotti A; Siravegna G; Torri V; Amatu A; Ghezzi S; Marrapese G; Palmeri L; Valtorta E; Cassingena A; Lauricella C; Vanzulli A; Regge D; Veronese S; Comoglio PM; Bardelli A; Marsoni S; Siena S
Lancet Oncol; 2016 Jun; 17(6):738-746. PubMed ID: 27108243
[TBL] [Abstract][Full Text] [Related]
22. Trastuzumab plus pertuzumab for HER2-amplified advanced colorectal cancer: Results from the drug rediscovery protocol (DRUP).
Spiekman IAC; Zeverijn LJ; Geurts BS; Verkerk K; Haj Mohammad SF; van der Noort V; Roepman P; de Leng WWJ; Jansen AML; Gootjes EC; de Groot DA; Kerver ED; van Voorthuizen T; Roodhart JML; Valkenburg-van Iersel LBJ; Gelderblom H; Voest EE; Verheul HMW
Eur J Cancer; 2024 May; 202():113988. PubMed ID: 38471288
[TBL] [Abstract][Full Text] [Related]
23. Membranous or Cytoplasmic HER2 Expression in Colorectal Carcinoma: Evaluation of Prognostic Value Using Both IHC & BDISH.
Buhmeida A; Assidi M; Al-Maghrabi J; Dallol A; Sibiany A; Al-Ahwal M; Chaudhary A; Abuzenadah A; Al-Qahtani M
Cancer Invest; 2018 Feb; 36(2):129-140. PubMed ID: 29504811
[TBL] [Abstract][Full Text] [Related]
24. BRAF, PIK3CA, and HER2 Oncogenic Alterations According to KRAS Mutation Status in Advanced Colorectal Cancers with Distant Metastasis.
Nam SK; Yun S; Koh J; Kwak Y; Seo AN; Park KU; Kim DW; Kang SB; Kim WH; Lee HS
PLoS One; 2016; 11(3):e0151865. PubMed ID: 26991109
[TBL] [Abstract][Full Text] [Related]
25. A phase 2 basket trial of combination therapy with trastuzumab and pertuzumab in patients with solid cancers harboring human epidermal growth factor receptor 2 amplification (JUPITER trial).
Takahashi K; Ishibashi E; Kubo T; Harada Y; Hayashi H; Kano M; Shimizu Y; Shirota H; Mori Y; Muto M; Ishioka C; Dosaka-Akita H; Matsubara H; Nishihara H; Sueoka-Aragane N; Toyooka S; Hirakawa A; Tateishi U; Miyake S; Ikeda S
Medicine (Baltimore); 2020 Aug; 99(32):e21457. PubMed ID: 32769873
[TBL] [Abstract][Full Text] [Related]
26. PI3K-driven HER2 expression is a potential therapeutic target in colorectal cancer stem cells.
Mangiapane LR; Nicotra A; Turdo A; Gaggianesi M; Bianca P; Di Franco S; Sardina DS; Veschi V; Signore M; Beyes S; Fagnocchi L; Fiori ME; Bongiorno MR; Lo Iacono M; Pillitteri I; Ganduscio G; Gulotta G; Medema JP; Zippo A; Todaro M; De Maria R; Stassi G
Gut; 2022 Jan; 71(1):119-128. PubMed ID: 33436496
[TBL] [Abstract][Full Text] [Related]
27. HER2 overexpression and amplification as a potential therapeutic target in colorectal cancer: analysis of 3256 patients enrolled in the QUASAR, FOCUS and PICCOLO colorectal cancer trials.
Richman SD; Southward K; Chambers P; Cross D; Barrett J; Hemmings G; Taylor M; Wood H; Hutchins G; Foster JM; Oumie A; Spink KG; Brown SR; Jones M; Kerr D; Handley K; Gray R; Seymour M; Quirke P
J Pathol; 2016 Mar; 238(4):562-70. PubMed ID: 26690310
[TBL] [Abstract][Full Text] [Related]
28. HER2 as an Emerging Oncotarget for Colorectal Cancer Treatment After Failure of Anti-Epidermal Growth Factor Receptor Therapy.
Takegawa N; Yonesaka K
Clin Colorectal Cancer; 2017 Dec; 16(4):247-251. PubMed ID: 28363756
[TBL] [Abstract][Full Text] [Related]
29. HER2-targeted therapies - a role beyond breast cancer.
Oh DY; Bang YJ
Nat Rev Clin Oncol; 2020 Jan; 17(1):33-48. PubMed ID: 31548601
[TBL] [Abstract][Full Text] [Related]
30. HER2 genomic amplification in circulating tumor DNA from patients with cetuximab-resistant colorectal cancer.
Takegawa N; Yonesaka K; Sakai K; Ueda H; Watanabe S; Nonagase Y; Okuno T; Takeda M; Maenishi O; Tsurutani J; Satoh T; Okamoto I; Nishio K; Tamura T; Nakagawa K
Oncotarget; 2016 Jan; 7(3):3453-60. PubMed ID: 26657506
[TBL] [Abstract][Full Text] [Related]
31. Pertuzumab : evolving therapeutic strategies in the management of HER2-overexpressing breast cancer.
O'Sullivan CC; Swain SM
Expert Opin Biol Ther; 2013 May; 13(5):779-90. PubMed ID: 23530718
[TBL] [Abstract][Full Text] [Related]
32. Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial.
Siena S; Di Bartolomeo M; Raghav K; Masuishi T; Loupakis F; Kawakami H; Yamaguchi K; Nishina T; Fakih M; Elez E; Rodriguez J; Ciardiello F; Komatsu Y; Esaki T; Chung K; Wainberg Z; Sartore-Bianchi A; Saxena K; Yamamoto E; Bako E; Okuda Y; Shahidi J; Grothey A; Yoshino T;
Lancet Oncol; 2021 Jun; 22(6):779-789. PubMed ID: 33961795
[TBL] [Abstract][Full Text] [Related]
33. Diagnosis and Treatment of ERBB2-Positive Metastatic Colorectal Cancer: A Review.
Strickler JH; Yoshino T; Graham RP; Siena S; Bekaii-Saab T
JAMA Oncol; 2022 May; 8(5):760-769. PubMed ID: 35238866
[TBL] [Abstract][Full Text] [Related]
34. [fam-] trastuzumab deruxtecan, antitumor activity is dependent on HER2 expression level rather than on HER2 amplification.
Takegawa N; Tsurutani J; Kawakami H; Yonesaka K; Kato R; Haratani K; Hayashi H; Takeda M; Nonagase Y; Maenishi O; Nakagawa K
Int J Cancer; 2019 Dec; 145(12):3414-3424. PubMed ID: 31087550
[TBL] [Abstract][Full Text] [Related]
35. Human epidermal growth factor receptor 2 (HER2) in advanced gastric cancer: where do we stand?
Roviello G; Aprile G; D'Angelo A; Iannone LF; Roviello F; Polom K; Mini E; Catalano M
Gastric Cancer; 2021 Jul; 24(4):765-779. PubMed ID: 33742317
[TBL] [Abstract][Full Text] [Related]
36. Pertuzumab for the treatment of human epidermal growth factor receptor type 2-positive metastatic breast cancer.
Chung C; Lam MS
Am J Health Syst Pharm; 2013 Sep; 70(18):1579-87. PubMed ID: 23988598
[TBL] [Abstract][Full Text] [Related]
37. Mind the target: human epidermal growth factor receptor 2 in colorectal cancer.
Saúde-Conde R; Rasschaert G; Bregni G; Hendlisz A; Sclafani F
Curr Opin Oncol; 2022 Jul; 34(4):382-388. PubMed ID: 35730499
[TBL] [Abstract][Full Text] [Related]
38. Combined blockade of MEK and PI3KCA as an effective antitumor strategy in HER2 gene amplified human colorectal cancer models.
Belli V; Matrone N; Napolitano S; Migliardi G; Cottino F; Bertotti A; Trusolino L; Martinelli E; Morgillo F; Ciardiello D; De Falco V; Giunta EF; Bracale U; Ciardiello F; Troiani T
J Exp Clin Cancer Res; 2019 Jun; 38(1):236. PubMed ID: 31164152
[TBL] [Abstract][Full Text] [Related]
39. Systematic literature review and meta-analysis of HER2 amplification, overexpression, and positivity in colorectal cancer.
Singh H; Kang A; Bloudek L; Hsu LI; Corinna Palanca-Wessels M; Stecher M; Siadak M; Ng K
JNCI Cancer Spectr; 2024 Jan; 8(1):. PubMed ID: 37815820
[TBL] [Abstract][Full Text] [Related]
40. Circulating tumor DNA-guided treatment with pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer: a phase 2 trial.
Nakamura Y; Okamoto W; Kato T; Esaki T; Kato K; Komatsu Y; Yuki S; Masuishi T; Nishina T; Ebi H; Sawada K; Taniguchi H; Fuse N; Nomura S; Fukui M; Matsuda S; Sakamoto Y; Uchigata H; Kitajima K; Kuramoto N; Asakawa T; Olsen S; Odegaard JI; Sato A; Fujii S; Ohtsu A; Yoshino T
Nat Med; 2021 Nov; 27(11):1899-1903. PubMed ID: 34764486
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
